Tuesday, February 9, 2016

Merck reaches to Australia (again) for licensing deal

Merck's efforts to re-organize and re-energize itself to boost production of profitable medicine has brought another licensing deal with Australian drugmaker Bionomics.

Merck reaches to Australia (again) for licensing deal

0 comments
In this Thursday, Feb. 28, 2013 photo, Merck scientist Meizhen Feng conducts research to discover new HIV drugs in West Point, Pa. Merck reports quarterly earnings on Tuesday, July 30, 3013. (AP Photo/Matt Rourke)
In this Thursday, Feb. 28, 2013 photo, Merck scientist Meizhen Feng conducts research to discover new HIV drugs in West Point, Pa. Merck reports quarterly earnings on Tuesday, July 30, 3013. (AP Photo/Matt Rourke)

Merck's efforts to re-organize and re-energize itself to boost production of profitable medicine has included more licensing deals with smaller companies.

Tuesday brought another deal with Bionomics, an Australian company that has worked with Merck previously and will now work on the hunt for medicine for Alzheimer's disease.

According to the Bionomics, and as noted in the Pharma Letter, Merck will pay for all research and development, including clinical development, and will be responsible for worldwide commercialization of any products from the collaboration.

Bionomics gets $20 million upfront and could receive up to $506 million for achievement of certain research and clinical development milestones and undisclosed royalties on any product sales. The Bionomics statement is here.

“We are very excited to work with Merck to progress new therapies for cognitive impairment in conditions such as Alzheimer’s disease,” Bionomics chief executive officer Deborah Rathjen said in a statement. “We believe that the combination of Bionomics’ innovative approach and technologies,within its ionX platform, has the potential to rapidly advance new treatments.”

Last year, the two companies struck a licensing deal to develop small molecule candidates for the treatment of chronic pain, including neuropathic pain.

Merck is based in Whitehouse Station, N.J., but has big operations in Montgomery County.

 

 

Staff Writer
0 comments
We encourage respectful comments but reserve the right to delete anything that doesn't contribute to an engaging dialogue.
Help us moderate this thread by flagging comments that violate our guidelines.

Comment policy:

Philly.com comments are intended to be civil, friendly conversations. Please treat other participants with respect and in a way that you would want to be treated. You are responsible for what you say. And please, stay on topic. If you see an objectionable post, please report it to us using the "Report Abuse" option.

Please note that comments are monitored by Philly.com staff. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable. Personal attacks, especially on other participants, are not permitted. We reserve the right to permanently block any user who violates these terms and conditions.

Additionally comments that are long, have multiple paragraph breaks, include code, or include hyperlinks may not be posted.

Read 0 comments
 
comments powered by Disqus
About this blog
David Sell blogs about the region's pharmaceutical industry. Follow him on Facebook.

Portions of this blog may also be found in the Inquirer's Sunday Health Section.

Reach David at dsell@phillynews.com or 215-854-4506.

David Sell Staff Writer
Also on Philly.com:
letter icon Newsletter